Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer - Marketscreener.com
PRRUF Stock | USD 0.20 0.00 0.00% |
Roughly 62% of Immutep's investor base is looking to short. The analysis of overall sentiment of trading Immutep Limited pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Immutep's historical and current headlines, can help investors time the market. In addition, many technical investors use Immutep Limited stock news signals to limit their universe of possible portfolio assets.
Immutep pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Immutep daily returns and investor perception about the current price of Immutep Limited as well as its diversification or hedging effects on your existing portfolios.
Immutep |
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer Marketscreener.com
Read at news.google.com
Immutep Fundamental Analysis
We analyze Immutep's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immutep using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immutep based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Immutep is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Immutep Limited Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immutep pink sheet to make a market-neutral strategy. Peer analysis of Immutep could also be used in its relative valuation, which is a method of valuing Immutep by comparing valuation metrics with similar companies.
Peers
Immutep Related Equities
CDTX | Cidara Therapeutics | 5.73 | ||||
ZURA | Zura Bio | 3.64 | ||||
ALXO | Alx Oncology | 2.11 | ||||
APLT | Applied Therapeutics | 0.88 | ||||
ENVB | Enveric Biosciences | 0.83 | ||||
OLMA | Olema Pharmaceuticals | 0.30 | ||||
VRDN | Viridian Therapeutics | 0.78 | ||||
AADI | Aadi Bioscience | 0.83 | ||||
ZNTL | Zentalis Pharmaceuticals | 1.28 | ||||
GPCR | Structure Therapeutics | 1.45 | ||||
CTMX | CytomX Therapeutics | 1.79 | ||||
ALVR | Allovir | 2.17 | ||||
SLN | Silence Therapeutics | 2.27 | ||||
CYTK | Cytokinetics | 3.16 | ||||
CGEM | Cullinan Oncology | 3.52 | ||||
CRNX | Crinetics Pharmaceuticals | 3.52 | ||||
IMMX | Immix Biopharma | 4.23 | ||||
ADCT | ADC Therapeutics | 4.55 | ||||
ELEV | Elevation Oncology | 5.19 | ||||
SANA | Sana Biotechnology | 7.35 | ||||
DSGN | Design Therapeutics | 8.79 |
Complementary Tools for Immutep Pink Sheet analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |